Wild-Type Transthyretin Amyloidosis
FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule transthyretin stabilizer, for the treatment of transthyretin amyloidosis with cardiomyopathy.
ALXN2220 for ATTR amyloidosis with cardiomyopathy granted fast track designation
AstraZeneca announced its rare disease unit, Alexion, has been granted fast track designation by the FDA for ALXN2220 for the treatment of transthyretin amyloidosis with cardiomyopathy.
Vutrisiran reduces mortality, CV events in ATTR amyloidosis with cardiomyopathy
Alnylam Pharmaceuticals announced the positive top-line results of the phase 3 HELIOS-B trial of its investigational RNA interfering therapy vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy.
Consider cardiac amyloidosis to avoid ‘missed opportunity’ of early intervention
Interest in transthyretin cardiac amyloidosis, or ATTR-CM, has grown in part due to three areas of recent advancement: imaging, recognition of the lesser-known disease and drug approvals.
Early diagnosis key for management, QOL in transthyretin amyloidosis
Taimur Sher, MBBS, MD a hematologist, internist and oncologist at the Mayo Clinic Cancer Center who leads the Multispecialty Amyloidosis Clinic at Mayo Clinic in Jacksonville, Florida, spoke with Healio about how to recognize and diagnose transthyretin amyloidosis, the newest FDA-approved treatments and the importance of genetic counseling in disease management.